Lacking TNBC datasets that received immunotherapy, we selected three cohorts that received anti-PDL1, anti-PD1, and anti-MAGE-A3 therapy in bladder cancer (BLCA) and skin melanoma (SKCM) to verify the immunotherapy response prediction value of the TRG score. This evidence concerns the gene CD274 and bladder transitional cell carcinoma.